Potassium Nitrate Drug Asset Due Diligence Report 2026

This Potassium Nitrate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Potassium Nitrate can convert its Small molecule drug profile and Not disclosed biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Potassium Nitrate (query alias: Potassium Nitrate)
Modality / target	Small molecule drug; Not disclosed; Not disclosed
Highest global status	Phase 2
Originator	Washington University School of Medicine
Active developers	Washington University School of Medicine

The MCP disease footprint includes Heart Failure. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
ChiCTR2600131001	Phase 3	Completed	35	Primary endpoint not disclosed in English source
ChiCTR2600130743	Phase 4	Completed	106	Primary endpoint not disclosed in English source
CTRI/2026/03/105703	Phase 3	Not Yet Recruiting	11	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Inorganic nitrate benefits contrast-induced nephropathy after coronary angiography for acute coronary syndromes: the NITRATE-CIN trial.

Phase 2; n=640; evaluation: Positive. Reported fields: CIN rates = 9.1 % ; CIN rates = 30.5 %

Acute inorganic nitrate intake increases regional insulin action in the brain: Results of a double-blind, randomized, controlled cross-over trial with abdominally obese men

Not Applicable; n=18; evaluation: Not stated in English source. Reported fields: Insulin Sensitivity = 7.0 mL/100 g/min

Targeting Pulsatile Load to Increase Exercise Capacity and Quality of Life After Aortic Valve Replacement for Severe Aortic Stenosis (PULSE AS)

Phase 2; n=5; evaluation: Not stated in English source. Reported fields: Other (Not Including Serious) Adverse Events = 2 Pts ; Other (Not Including Serious) Adverse Events = 0 Pts

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Potassium Nitrate addresses Heart Failure. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
No matched asset or comparable transaction returned.

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Application of potassium nitrate in preparation of drugs for preventing and treating calculus”. The milestone feed surfaced a patent-application signal described as “Oral care compositions containing a GEL network phase and potassium nitrate”. The milestone feed surfaced a patent-application signal described as “High Dose Dehydroepiandrosterone as Anticancer Treatment With Multi-faceted Reconstitution of Otherwise Depleted Metabolites”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO